Suvoda Launches eCOA-Specific Language and Design Toolkit as Solution Moves to Second Phase of Early Adopter Program
PR99103
PHILADELPHIA, Dec. 7, 2022 /PRNewswire=KYODO JBN/ --
--Practical, innovative functionality seeks to alleviate eCOA burdens, reduce
time-to-launch, and improve site, clinician, and patient experience.
Suvoda LLC, a global clinical trial technology company that specializes in
complex studies in therapeutic areas such as oncology, central nervous system
(CNS), and rare disease, today announced that as part of its single platform
rollout, its electronic clinical outcome assessments (eCOA) solution is moving
to the second phase of the Early Adopter program. This solution, designed to
work seamlessly with Suvoda IRT and eConsent, focuses on tackling the
historical inefficiencies that continue to plague eCOA, such as gaps in overall
delivery and execution quality, time consuming translations and localization
processes, and logistics related to device management.
Logo - https://mma.prnewswire.com/media/1759317/Suvoda_Logo.jpg
"eCOA is not a new concept, yet the full promise of this eClinical technology
has yet to be realized by sponsors and CROs, and most importantly, clinical
trial participants," explains Jill Platko, vice president, scientific services
at Suvoda. "In support of Suvoda's mission to enhance the clinical trial
process, Suvoda did not want to simply offer another eCOA solution. But
instead, wanted to dive into the gaps that make current eCOA implementations so
challenging."
Practical Innovations Simplify eCOA Implementations
As it moves into the next phase of the early adopter program, Suvoda's eCOA
solution incorporates input from its customers and includes reimagined
processes in four key areas that have proven critical to successful eCOA
implementations:
1. Questionnaire Design and Creation
Suvoda eCOA introduces a unique, easy-to-use, configuration-based toolkit
designed to simplify and accelerate eCOA set-up and delivery. Within it, Suvoda
offers a proprietary domain-specific language and creation tool that is
tailor-made for eCOA questionnaires.
An innovative addition to the current eCOA product landscape, this tool
simplifies eCOA questionnaire creation, accelerates localization, and improves
access to previews. Questionnaires also can be defined, adjusted, translated,
validated, and reused across modalities and devices, all in a
regulatory-compliant environment. This licensing and localization functionality
includes direct access for translation vendors to further streamline workflows
and timelines to better meet the needs of any protocol, now and in the future.
2. Device Logistics
Drawing on its 10 years of experience managing the most urgent moments across
thousands of trials around the world with its IRT solution and support, Suvoda
is uniquely positioned to set the standard for eCOA device logistics. eCOA
prioritizes the user experience. With proven processes for clinical trial
supply chain and data management already in place, Suvoda eCOA will further
improve real-time data capture and simplify device logistics for global
clinical trial sites, sponsors, and patients.
3. Real-time Customer Care/Support
With the global capability of its devices and sites, Suvoda supports
mission-critical issues in real-time — sustaining its reputation of responsive,
reliable customer care. Congruous with its consistently high client
satisfaction scores, the company prioritized providing the same level of global
support excellence for its eCOA customers.
4. Patient Data Integrity through a Single Platform Approach
Suvoda's eCOA, paired with its market-leading IRT solution on a single,
organically-built platform along with eConsent, ensures a worry-free,
streamlined approach by reducing the number of integrations required for a
clinical trial. This transparent integration ensures that patient data will be
collected and shared seamlessly across the platform, giving users greater
accessibility to data that is normalized, compliant, unified, and ready for
analysis. This is a significant advancement that improves data integrity,
positively impacts trial timelines and output, and creates a more unified user
experience for patients and site users.
"With a proven track record in services delivery and execution across thousands
of clinical trials around the world, Suvoda specializes in managing the demands
of mission-critical, time-sensitive patient interactions," said Suvoda Chief
Product Officer E.K. Koh. "We are logistics leaders in the clinical trial space
— and the addition of eCOA to our platform further ensures we are centering the
patient digital experience without increasing complexity."
Suvoda is still accepting participants in the Early Adopter program as eCOA
moves into the next phase. Additional enhancements will be released in early
2023. Click here (
) to inquire about becoming an early adopter.
About Suvoda
Suvoda is a global clinical trial technology company that specializes in
complex, life-sustaining studies in therapeutic areas like oncology, central
nervous system (CNS), and rare disease. Founded in 2013 by experts in eClinical
technologies, Suvoda empowers clinical trial professionals to manage the most
urgent moments in the most urgent trials through advanced software solutions
delivered on a single platform. Headquartered outside Philadelphia, Suvoda also
maintains offices in Portland, OR, Barcelona, Spain, Bucharest, Romania and
Tokyo, Japan. The company consistently boasts a Net Promoter Score (NPS) of
close to 70, far exceeding the technology industry average of 50, and has been
selected by trial sponsors and CROs to support more than 1,000 trials across 65
countries. To learn more, visit suvoda.com (
. Follow Suvoda on Twitter (
) and LinkedIn (
).
Media Contact: Morgan Reese, morgan.reese@clydegroup.com
SOURCE Suvoda LLC
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。
